P. Debourdeau

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Malika Chaouche · 1 shared paper, 2023 · strength 0.31
   • Paper Which events to consider in the study of venous thromboses in pancreatic cancer patients? DOI 10.1016/j.ejim.2022.11.017↗
2. Dominique Farge · 2 shared papers, 2015–2018 · strength 0.13
   • Paper [Venous thromboembolism and pancreatic cancer]. DOI 10.1016/j.jdmv.2018.05.003↗
   • Paper Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. DOI 10.1016/s1499-3872(15)60397-6↗
3. Franck Bonnetain · 2 shared papers, 2017–2019 · strength 0.13
   • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
   • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
4. Christophe Tournigand · 2 shared papers, 2017–2019 · strength 0.13
   • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
   • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
5. Christophe Louvet · 2 shared papers, 2017–2019 · strength 0.13
   • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
   • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
6. Julien Taı̈eb · 2 shared papers, 2017–2019 · strength 0.13
   • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
   • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
7. Pascal R. Hammel · 2 shared papers, 2017–2019 · strength 0.13
   • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
   • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
8. Jean‐Baptiste Bachet · 2 shared papers, 2017–2019 · strength 0.13
   • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
   • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
9. Corinne Frère · 1 shared paper, 2018 · strength 0.08
   • Paper [Venous thromboembolism and pancreatic cancer]. DOI 10.1016/j.jdmv.2018.05.003↗
10. Louis Buscail · 1 shared paper, 2018 · strength 0.08
    • Paper [Venous thromboembolism and pancreatic cancer]. DOI 10.1016/j.jdmv.2018.05.003↗
11. Barbara Bournet · 1 shared paper, 2018 · strength 0.08
    • Paper [Venous thromboembolism and pancreatic cancer]. DOI 10.1016/j.jdmv.2018.05.003↗
12. Amélie Anota · 1 shared paper, 2019 · strength 0.08
    • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
13. Romain Cohen · 1 shared paper, 2019 · strength 0.08
    • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
14. Émilie Charton · 1 shared paper, 2019 · strength 0.08
    • Paper Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel p… DOI 10.1002/cam4.2311↗
15. Thierry André · 1 shared paper, 2017 · strength 0.05
    • Paper Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic p… DOI 10.1016/s2468-1253(17)30046-8↗
16. Igor Sielezneff · 1 shared paper, 2015 · strength 0.05
    • Paper Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. DOI 10.1016/s1499-3872(15)60397-6↗
17. Laëtitia Dahan · 1 shared paper, 2015 · strength 0.05
    • Paper Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. DOI 10.1016/s1499-3872(15)60397-6↗
18. Mehdi Ouaïssi · 1 shared paper, 2015 · strength 0.05
    • Paper Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. DOI 10.1016/s1499-3872(15)60397-6↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.